TY - JOUR T1 - How rare and common risk variation jointly affect liability for autism spectrum disorder JF - medRxiv DO - 10.1101/2020.10.27.20220095 SP - 2020.10.27.20220095 AU - Lambertus Klei AU - Lora Lee McClain AU - Behrang Mahjani AU - Klea Panayidou AU - Silvia De Rubeis AU - Anna-Carin Säll Grahnat AU - Gun Karlsson AU - Yangyi Lu AU - Nadine Melhem AU - Xinyi Xu AU - Abraham Reichenberg AU - Sven Sandin AU - Christina M. Hultman AU - Joseph D. Buxbaum AU - Kathryn Roeder AU - Bernie Devlin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/31/2020.10.27.20220095.abstract N2 - Background Genetic studies have implicated rare and common variation in liability for autism spectrum disorder (ASD). Of the discovered risk variants, those rare in the population invariably have large impact on liability, while common variants have small effects. Yet, collectively, common risk variants account for the majority of population-level variability. How these rare and common risk variants jointly affect liability for individuals requires further study.Methods To explore how common and rare variants jointly affect liability, we assessed two cohorts of ASD families characterized for rare and common genetic variation (Simons Simplex Collection and Population-Based Autism Genetics & Environment Study). We analyzed data from 3,011 affected subjects, as well as two cohorts of unaffected individuals characterized for common genetic variation: 3,011 subjects matched for ancestry to ASD subjects; and 11,950 subjects for estimating allele frequencies. We used genetic scores, which assessed the relative burden of common genetic variation affecting risk for ASD (henceforth burden), and determined how this burden was distributed among three subpopulations: ASD subjects who carry a rare damaging variant implicated in risk for ASD (mutation carriers); ASD subjects who do not (non-carriers); and unaffected subjects, who are assumed to be non-carriers.Results Burden harbored by ASD subjects is stochastically greater than that harbored by control subjects. For mutation carriers, their average burden is intermediate between non-carrier ASD and control subjects. Both carrier and non-carrier ASD subjects have greater burden, on average, than control subjects. The effects of common and rare variants likely combine additively to determine individual-level liability.Limitations Only 258 ASD subjects were known mutation carriers. This relatively small subpopulation limits this study to characterizing general patterns of burden, as opposed to effects of specific mutations or genes. Also, a small fraction of subjects that are categorized as non-carriers could be mutation carriers.Conclusions Liability arising from common and rare risk variation likely combine additively to determine risk for any individual diagnosed with ASD. On average, ASD subjects carry a substantial burden of common risk variation, even if they also carry a rare mutation affecting risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants from the NIMH, the Simons Foundation and the Seaver Foundation. Specifically, National Institute of Mental Health grants R37MH057881 (to B.D. and K.R.), R01MH097849 (to J.D.B.), U01MH111661 (to J.D.B.), and U01MH111658 (to B.D. and K.R.); a Simons Foundation grant (SF575547) to K.R., B.D., and Haiyuan Yu; and the Seaver Foundation (to J.D.B, S.D.R., B. M. and S.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs at Mt Sinai and University of PittsburghAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll rare variant data used in this manuscript are available in NIH- or SFARI-controlled data sets. Common genetic variation has been used by and is available via the Psychiatric Genomics Consortium (PAGES) or from SFARI.ADautistic disorderASDAutism spectrum disorderCLScluster-specificCNVcopy number varianteMERGEElectronic MEdical Records and Genomics NetworkG-BLUPGenomic-Best Linear Unbiased PredictionGCTAGenome-wide Complex Trait AnalysisGPgenomic predictionGRMgenomic relationship matrixGWASgenomewide association studiesHRCHaplotype Reference ConsortiumLDlinkage disequilibriumMISde novo missense variantPAGESPopulation-Based Autism Genetics & Environment StudyPOPpopulationPRSpolygenic risk scorepTDTpolygenic TransmissionPTVProtein truncating variantQCquality controlSSCSimons Simplex CollectionSCZschizophreniaWGRSweighted genomic risk score ER -